Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cetuximab-based PROteolysis targeting chimera for effectual downregulation of NSCLC with varied EGFR mutations.

International journal of biological macromolecules - 1 Dec 2023

Vartak Richa, Deore Bhavesh, Sanhueza Carlos A, Patel Ketan

Abstract excerpt

PROteolysis Targeting Chimeras (PROTACs) showed tremendous therapeutic potential in degrading several oncoproteins including undruggable proteins. PROTACs are bifunctional molecules where one-part binds to target protein while the other end recruits protein degradation machinery. With the unveiling advancements in the field of PROTACs, we explored a combinatorial approach by developing antibody-based PROTAC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Down-Regulation

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Proteolysis

Source

Identifiers

PMID: 37598823
DOI: 10.1016/j.ijbiomac.2023.126413

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cetuximab-based PROteolysis targeting chimera for effectual downregulation of NSCLC with varied EGFR mutations.PMID 37598823Read ↗

Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems.Semantic proximity Read ↗

Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686.Semantic proximity Read ↗

Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands.Semantic proximity Read ↗

Proteolysis targeting chimeras in non-small cell lung cancer.Semantic proximity Read ↗

[Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy].Semantic proximity Read ↗

Discovery of highly potent and selective CRBN-recruiting EGFRL858R/T790M degraders in vivo.Semantic proximity Read ↗

Targeting the Interplay of Proteins through PROTACs for the Management of Cancer and Associated DisordersSemantic proximity Read ↗

New-generation advanced PROTACs as potential therapeutic agents in cancer therapySemantic proximity Read ↗

Cancer Selective Target Degradation by Folate-Caged PROTACsSemantic proximity Read ↗

PROTAC’ing oncoproteins: targeted protein degradation for cancer therapySemantic proximity Read ↗

Targeted Protein Degradation in Lung Cancer: The Emerging Role of PROTAC Technology and E3 LigasesSemantic proximity Read ↗

Discovery of novel EGFR-PROTACs capable of degradation of multiple EGFR-mutated proteins.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.